Biocon Ltd, an Indian biopharmaceutical company, plans to list its biosimilars division on stock exchanges by March 2026. The company aims to launch five new biosimilars in the U.S. market, targeting a double-digit market share. Before the public listing, Biocon intends to complete the integration of its acquired biosimilars business from Viatris Inc. and refinance existing debt. These strategic steps are designed to strengthen the company’s financial position and operational efficiency.
Biocon Ltd, a leading Indian biopharmaceutical company, announced plans to list its biosimilars division on stock exchanges by March 2026. This strategic move aims to enhance the company’s market presence and financial growth.
Expansion in the U.S. Market
Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, is set to launch five new biosimilars in the U.S. market in the upcoming fiscal year, starting in April. The company targets a double-digit market share for these new products, focusing on therapeutic areas such as oncology, immunology, and diabetes. Currently, Biocon Biologics holds a 20% market share in the U.S. biosimilars market.
Strategic Milestones
Before proceeding with the public listing, Biocon plans to complete the integration of its acquired biosimilars business from Viatris Inc. and refinance existing debt. These steps are crucial to strengthen the company’s financial position and operational efficiency.
Global Market Outlook
The global biosimilars market is projected to grow significantly, with estimates reaching $75 billion by 2030. Biocon aims to capitalize on this growth by expanding its product portfolio and increasing its market share in key regions, including the United States and Europe.
This strategic initiative underscores Biocon’s commitment to enhancing healthcare affordability and accessibility through the development and distribution of high-quality biosimilars.
